-
公开(公告)号：EP3922647A1
公开(公告)日：2021-12-15
申请号：EP20747692.0
申请日：2020-01-31
发明人： GU, Xiaoling , YE, Xin , GE, Hu , TAO, Weikang
IPC分类号： C07K16/28 , C12N15/13 , C12N15/63 , C12N1/21 , C12N1/19 , C12N1/15 , C12N5/10 , A61K39/395 , A61K48/00 , A61P35/00 , A61P31/00 , A61P33/00 , A61P29/00
摘要： Provided are an anti-PD-1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Specifically, provided are a humanized anti-PD-1 antibody containing a specific CDR region and an antigen-binding fragment thereof, a pharmaceutical composition containing the anti-PD-1 antibody and the antigen-binding fragment thereof, and a used thereof as medicament. In particular, provided is a use of the humanized anti-PD-1 antibody in the preparation of the medicament for treating PD-1 associated diseases or disorders.
-
公开(公告)号：EP3741777A1
公开(公告)日：2020-11-25
申请号：EP19738076.9
申请日：2019-01-09
发明人： GU, Xiaoling , JIANG, Jiahua , ZHANG, Lei , HU, Qiyue , GU, Jinming , TAO, Weikang
IPC分类号： C07K16/28 , A61K39/395 , C12N15/13 , A61P35/00
摘要： A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof, and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
-
公开(公告)号：EP3936526A1
公开(公告)日：2022-01-12
申请号：EP20766028.3
申请日：2020-03-05
发明人： GU, Xiaoling , YE, Xin , HU, Bing , GE, Hu , TAO, Weikang
IPC分类号： C07K19/00 , C12N15/62 , A61K39/395 , A61P35/00
摘要： Provided are a bifunctional fusion protein and pharmaceutical use thereof. Specifically, provided are a bifunctional fusion protein comprising an SIRPγ peptide variant and an anti-human PD-L1 antibody, an SIRPγ peptide variant, and pharmaceutical use thereof. The bifunctional fusion protein can specifically bind PD-L1 and CD47 to block the binding of PD-L1 or CD47 to a receptor or ligand thereof. In addition, also provided are preparation and application of the bifunctional fusion protein, and treatment of cancers and immune-related diseases.
-
4.发明公开
公开(公告)号：EP4339207A1
公开(公告)日：2024-03-20
申请号：EP22806818.5
申请日：2022-05-12
发明人： YING, Hua , MAO, Langyong , GU, Xiaoling , TAO, Weikang
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61K45/00
摘要： The present disclosure relates to an antigen-binding molecule specifically binding to RANKL and NGF, and a medical use thereof. Specifically, provided are a novel anti-RANKL antibody, a bispecific antibody targeting RANKL and NGF, a preparation method for the antibody, and a use thereof in treatment or prevention of diseases.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
